Immune Thrombocytopenia In Us Clinical Practice: Incidence And Healthcare Utilization/Expenditures In The First 12 Months Following Diagnosis

Background: Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by low platelet count due to increased platelet destruction and suboptimal platelet production, and can lead to serious bleeding events. While some evidence on the epidemiology of ITP is available, such data are based on ex-US populations or are now over a decade old. Moreover, little data exist on the healthcare burden of ITP, especially in the early (i.e., 12-month) period following diagnosis. Accordingly, a new study was undertaken to characterize the incidence of ITP as well as healthcare utilization and expenditures during the early (e)ITP period in the US.